Vertex Pharmaceuticals (VRTX) news

Bio-pharmaceutical stocks rose in regular trading, with Eli Lilly up 3.9%, Vertex Pharmaceuticals gaining 1.6% and Regeneron Pharmaceuticals rising 2.1%.

Frazier Life Sciences Acquisition Corp II prices IPO at $10/shr

Frazier Life Sciences Acquisition Corp II (FLACU) has priced its initial public offering at $10 per share, raising capital for its targeted investments in the biotechnology sector. The company, part of the broader Frazier Life Sciences platform, is managed by extensive experience in healthcare .…

Bio-pharmaceutical stocks fell in regular trading, with Vertex Pharmaceuticals down 3.7%, AbbVie falling 2.4% and Merck sliding 2.2%.

Vertex Pharmaceuticals Incorporated: BofA global research cuts price objective to $667 from $672

Vertex Pharmaceuticals Incorporated (VRTX) has seen a recent adjustment in its price objective by BofA Global Research, which reduced its target to $667 from $672. This change, while modest, reflects ongoing evaluations of the company's stock potential amid evolving market conditions and…

Bio-pharmaceutical stocks fell in regular trading, with Regeneron down 2.7%, Vertex Pharmaceuticals falling 1.7% and Amgen sliding 1.7%.

Bio-pharmaceutical stocks experienced declines in regular trading on October 1, 2026, with Regeneron Pharmaceuticals (REGN) down 2.7%, Vertex Pharmaceuticals (VRTX) falling 1.7%, and Amgen (AMGN) also sliding 1.7%. The sector has been under pressure amid ongoing challenges related to competitive…